Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of “Buy” by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given an average rating of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $20.83.

Several research analysts recently issued reports on STOK shares. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Leerink Partners began coverage on shares of Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, November 6th. Finally, Leerink Partnrs upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research note on Friday, October 11th.

Stoke Therapeutics Stock Performance

STOK stock opened at $12.03 on Friday. The firm has a 50-day simple moving average of $13.06 and a two-hundred day simple moving average of $13.80. Stoke Therapeutics has a one year low of $3.77 and a one year high of $17.58. The firm has a market cap of $637.23 million, a price-to-earnings ratio of -5.73 and a beta of 0.95.

Stoke Therapeutics (NASDAQ:STOK) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. As a group, equities analysts predict that Stoke Therapeutics will post -2.03 earnings per share for the current fiscal year.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, major shareholder Skorpios Trust sold 1,937,500 shares of the business’s stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares of the company’s stock, valued at approximately $125,131,843.05. The trade was a 17.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently made changes to their positions in STOK. Quest Partners LLC acquired a new stake in Stoke Therapeutics during the second quarter valued at $29,000. Nisa Investment Advisors LLC increased its stake in shares of Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after purchasing an additional 1,038 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Stoke Therapeutics in the 2nd quarter worth about $123,000. State Board of Administration of Florida Retirement System purchased a new position in Stoke Therapeutics during the first quarter worth approximately $141,000. Finally, Intech Investment Management LLC purchased a new position in Stoke Therapeutics during the third quarter worth approximately $160,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.